PRT062607 Achieves Complete Inhibition of the Spleen Tyrosine Kinase at Tolerated Exposures Following Oral Dosing in Healthy Volunteers

Coffey, G., Rani, A., Betz, A., Pak, Y., Haberstock-Debic, H., Pandey, A., Hollenbach, S., Gretler, D.D., Mant, T., Jurcevic, S. and Sinha, U. 2017. PRT062607 Achieves Complete Inhibition of the Spleen Tyrosine Kinase at Tolerated Exposures Following Oral Dosing in Healthy Volunteers. Journal of Clinical Pharmacology . 57 (2), p. 194–210. doi:10.1002/jcph.794

TitlePRT062607 Achieves Complete Inhibition of the Spleen Tyrosine Kinase at Tolerated Exposures Following Oral Dosing in Healthy Volunteers
AuthorsCoffey, G., Rani, A., Betz, A., Pak, Y., Haberstock-Debic, H., Pandey, A., Hollenbach, S., Gretler, D.D., Mant, T., Jurcevic, S. and Sinha, U.
Abstract

The spleen tyrosine kinase (SYK) regulates immune cell activation in response to engagement of a variety of receptors,making it an intriguing target for the treatment of inflammatory and autoimmune disorders as well as certain B-cell malignancies.We have previously reported on the discovery and preclinical characterization of PRT062607,a potent and highly selective inhibitor of SYK that exhibits robust anti-inflammatory activity in a variety of animal models.Here we present data from our first human studies aimed at characterizing the pharmacokinetics (PK),pharmacodynamics (PD), and safety of PRT062607 in healthy volunteers following single and multiple oral administrations.PRT062607 demonstrated a favorable PK profile and the ability to completely inhibit SYK activity in multiple whole-blood assays.The PD half-life in the more sensitive assays was approximately 24 hours and returned to predose levels by 72 hours.Selectivity for SYK was observed at all dose levels tested.Analysis of the PK/PD relationship indicated an IC50 of 324 nM for inhibition of B-cell antigen receptor-mediated B-cell activation and 205 nM for inhibition of FcRI-mediated basophil degranulation. PRT062607was safe and well tolerated acrossthe entire range ofdoses.Clinical PK/PDwas related to in vivo anti-inflammatoryactivity of PRT062607 in the rat collagen-induced arthritis model, which predicts that therapeutic concentrations may be safely achieved in humans for the treatment of autoimmune disease.PRT062607 has a desirable PK profile and is capable of safely,potently,and selectively suppressing SYK kinase function in humans following once-daily oral dosing.

KeywordsSYK,PRT062607,autoimmune,allergy,lymphoma,immunopharmacology
JournalJournal of Clinical Pharmacology
Journal citation57 (2), p. 194–210
ISSN0091-2700
Year2017
PublisherSage
Publisher's versionJCPH-57-194.pdf
Digital Object Identifier (DOI)doi:10.1002/jcph.794
Publication dates
Published online17 Aug 2016
Published in printFeb 2017
Published17 Aug 2016
LicenseCC BY-NC-ND 4.0

Related outputs

Endocrine Resistance in Hormone Receptor Positive Breast Cancer–From Mechanism to Therapy
Rani, A., Stebbing, J., Giamas, G. and Murphy, J.J. 2019. Endocrine Resistance in Hormone Receptor Positive Breast Cancer–From Mechanism to Therapy. Frontiers in endocrinology. 10, p. 245. doi:10.3389/fendo.2019.00245

HES1 in immunity and cancer
Rani, A., Greenlaw, R., Smith, R.A. and Galustian, C. 2016. HES1 in immunity and cancer. Cytokine & Growth Factor Reviews. 30, pp. 113-117. doi:10.1016/j.cytogfr.2016.03.010

STAT5 in Cancer and Immunity
Murphy, J.J. and Rani, A. 2016. STAT5 in Cancer and Immunity. Journal of Interferon & Cytokine Research. 36 (4), pp. 226-237. doi:10.1089/jir.2015.0054

The Notch target Hes1, is a STAT5 target gene with implications in cancer
Rani, A., Greenlaw, R., Galustian, C. and Murphy, J.J. 2015. The Notch target Hes1, is a STAT5 target gene with implications in cancer. 2015 Meeting of the ICIS in Bamberg, Germany, October 11th -14th. Bamberg, Germany Oct 2015 doi:10.1016/j.cyto.2015.08.214

Permalink - https://westminsterresearch.westminster.ac.uk/item/q1q2q/prt062607-achieves-complete-inhibition-of-the-spleen-tyrosine-kinase-at-tolerated-exposures-following-oral-dosing-in-healthy-volunteers


Share this
Tweet
Email